Portal de Periódicos da CAPES

Consensus review of the clinical utility of dna cytometry in carcinoma of the breast

1993; Wiley; Volume: 14; Issue: 5 Linguagem: Inglês

10.1002/cyto.990140505

1097-0320

David W. Hedley, Gary M. Clark, Cees J. Cornelisse, D. Killander, Timothy E. Kute, Douglas E. Merkel,

Breast Cancer Treatment Studies

CytometryVolume 14, Issue 5 p. 482-485 Special ReportFree Access Consensus review of the clinical utility of dna cytometry in carcinoma of the breast† David W. Hedley, Corresponding Author David W. Hedley Departments of Medicine and Pathology, Princess Margaret Hospital, Toronto, Ontario, CanadaDepts. of Medicine and Pathology, Princess Margaret Hospital, Toronto, Ontario, CanadaSearch for more papers by this authorGary M. Clark, Gary M. Clark University of Texas Health Science Center, Division of Medical Oncology, San Antonio, TexasSearch for more papers by this authorCees J. Cornelisse, Cees J. Cornelisse Department of Pathology, University of Leiden, Leiden, The NetherlandsSearch for more papers by this authorDick Killander, Dick Killander Department of Oncology, University of Lund, Lund, SwedenSearch for more papers by this authorTimothy Kute, Timothy Kute Department of Pathology, Bowman Gray School of Medicine, Winston-Salem, North CarolinaSearch for more papers by this authorDouglas Merkel, Douglas Merkel Department of Medical Oncology, Evanston Hospital, Evanston, IllinoisSearch for more papers by this author David W. Hedley, Corresponding Author David W. Hedley Departments of Medicine and Pathology, Princess Margaret Hospital, Toronto, Ontario, CanadaDepts. of Medicine and Pathology, Princess Margaret Hospital, Toronto, Ontario, CanadaSearch for more papers by this authorGary M. Clark, Gary M. Clark University of Texas Health Science Center, Division of Medical Oncology, San Antonio, TexasSearch for more papers by this authorCees J. Cornelisse, Cees J. Cornelisse Department of Pathology, University of Leiden, Leiden, The NetherlandsSearch for more papers by this authorDick Killander, Dick Killander Department of Oncology, University of Lund, Lund, SwedenSearch for more papers by this authorTimothy Kute, Timothy Kute Department of Pathology, Bowman Gray School of Medicine, Winston-Salem, North CarolinaSearch for more papers by this authorDouglas Merkel, Douglas Merkel Department of Medical Oncology, Evanston Hospital, Evanston, IllinoisSearch for more papers by this author First published: 1993 https://doi.org/10.1002/cyto.990140505Citations: 141 † These consensual guidelines and recommendations address the potential utility of DNA cytometry in characterizing human malignancies. They are provided to inform laboratory personnel, pathologists, and clinicians about DNA cytometry. For individual patients, use of DNA cytometry, selection of specific techniques, and interpretation and utilization of results remains the responsibility of the attending physicians. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Literature Cited 1 Auer G, Eriksson E, Azavedo E, Caspersson T, Wallgren A: Prognostic significance of nuclear DNA content in mammary adenocarcinomas in humans. Cancer Res 44: 394– 396, 1984. 2 Baak JP, Chin D, van Diest PJ, Ortiz R, Matze-Cok P, Bacus SS: Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer. Lab Invest 64: 215– 223, 1991. 3 Baildam AD, Zaloudik J, Howell A, Barnes DM, Turnbull L, Moore M, Sellwood RA: DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. Br J Cancer 55: 553– 560, 1987. 4 Beerman H, Smit VT, Kluin PM, Bonsing BA, Hermans J, Cornelisse CJ: Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer. Cytometry 12: 147– 154, 1991. 5 Beerman H, Bonsing BA, van de Vijver MJ, Hermans J, Kluin PM, Caspers RJ, van de Velde CJ, Cornelisse CJ: DNA ploidy of primary breast cancer and local recurrence after breast-conserving therapy. Br J Cancer 64: 139– 143, 1991. 6 Beerman H, Kluin M, Hermans J, van de Velde CJH, Cornelisse CJ: Prognostic significance of DNA-ploidy in a series of 690 primary breast cancer patients. Int J Cancer 45: 34– 39, 1990. 7 Blanco G, Holli K, Heikkinen M, Kallioniemi OP, Taskinen P: Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological grading. Br J Cancer 62: 142– 146, 1990. 8 Clark GM, Mathieu MC, Owens MA, Dressler LG, Eudey L, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff MD, et al: Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 10: 428– 432, 1992. 9 Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627– 633, 1989. 10 Cornelisse CJ, van de Velde CJ, Caspers RJ, Moolenaar AJ, Hermans J: DNA ploidy and survival in breast cancer patients. Cytometry 8: 225– 234, 1987. 11 Coulson PB, Thornthwaite JT, Woolley TW, Sugarbaker EV, Seckinger D: Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival. Cancer Res 44: 4187– 4196, 1984. 12 Dowle CS, Owainati A, Robins A, Burns K, Ellis IO, Elston CW, Blamey RW: Prognostic significance of the DNA content of human breast cancer. Br J Surg 74: 133– 136, 1987. 13 Eskelinen M, Lipponen P, Papinaho S, Aaltomaa S, Kosma V-M, Klemi P, Syrjanen K: DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer. Int J Cancer 51: 555– 561, 1992. 14 Fallenius AG, Auer GU, Carstensen JM: Prognostic significance of DNA measurements in 409 consecutive breast cancer patients. Cancer 62: 331– 341, 1988. 15 Fallenius AG, Franzn SA, Auer GU: Predictive value of nuclear DNA content in breast cancer in relation to clinical and morphologic factors. Cancer 62: 521– 530, 1988. 16 Ferno M, Baldetorp B, Borg A, Olsson H, Sigurdsson H, Killander D: Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome. Acta Oncologica 31: 157– 165, 1992. 17 Ferno M, Baldetorp B, Ewers SB, Idvall I, Olsson H, Sigurdsson H, Killander D: One or multiple samplings for flow cytometric DNA analyses in breast cancer—prognostic implications? Cytometry 13: 241– 249, 1992. 18 Fisher B, Gunduz N, Costantino J, Fisher ER, Edmond C, Mamounas EP, Siderits R: DNA flow cytometric analysis of primary operable breast cancer: Relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04. Cancer 68: 1465– 1475, 1991. 19 Gnant MFX, Blijham GH, Reiner A, Reiner G, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R: DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer:10 year results of a randomised study. Eur J Cancer 28: 711– 716, 1992. 20 Haag D, Feichter G, Goerttler K, Kaufmann M: Influence of Systematic Errors on the evaluation of the S Phase portions from DNA distributions of solid tumors as shown for 328 breast carcinomas. Cytometry 8: 377– 385, 1987. 21 Hedley DW, Rugg CA, Gelber RD: Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res 47: 4729– 4735, 1987. 22 Isola J, Visakorpi T, Holli K, Kallioniemi OP: Association of over-expression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. JNCI 84: 1109– 1114, 1992. 23 Kallioniemi OP, Visakorpi T, Holli K, Heikkinen A, Isola J, Koivula T: Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. Cytometry 12: 413– 421, 1991. 24 Kallioniemi OP, Joensuu H, Klemi P, Koivula T: Inter-laboratory comparison of DNA flow cytometric results from paraffin-embedded breast carcinomas. Breast Cancer Research &Treatment 17: 59– 61, 1990. 25 Kallioniemi OP, Blanco G, Alavaikko M, Hietanen T, Mattila J, Lauslahti K, Lehtinen M, Koivula T: Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and s-phase fraction: a proposed classification of DNA histograms in breast cancer. Cancer 62: 2183– 2190, 1988. 26 Kallioniemi OP, Hietanen T, Mattila J, Lehtinen M, Lauslahti K, Koivula T: Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. Eur J Cancer Clin Oncol 23: 277– 282, 1987. 27 Klintenberg C, Stål O, Nordenskjold B, Wallgren A, Arvidsson S, Skoog L: Proliferative index, cytosol estrogen receptor and axillary node status as prognostic predictors in human mammary carcinoma. Breast Cancer Research &Treatment 7 (Suppl): 99– 106, 1986. 28 Kute TE, Muss HB, Cooper MR, Case LD, Buss D, Stanley V, Gregory B, Galleshaw J, Booher K: The use of flow cytometry for the prognosis of stage II adjuvant treated breast cancer patients. Cancer 66: 1810– 1816, 1990. 29 Kute TE, Gregory B, Galleshaw J, Hopkins M, Buss D, Case D: How reproducible are flow cytometry data from paraffin-embedded blocks? Cytometry 9: 494– 498, 1988. 30 Muss HB, Kute TE, Case LD, Smith LR, Booher C, Long R, Kammire L, Gregory B, Brockschmidt JK: The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer. Cancer 64: 1894– 1900, 1989. 31 Noguchi M, Taniya T, Ohta N, Koyasaki N, Miyazaki I, Mizukami Y: Lymph node metastases versus DNA ploidy as prognostic factors for invasive ductal carcinoma of the breast. Breast Cancer Research &Treatment 19: 23– 31, 1991. 32 O'Reilly SM, Camplejohn RS, Barnes DM, Millis RR, Rubens RD, Richards MA: Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry [see comments]. J Clin Oncol 8: 2040– 2046, 1990. 33 O'Reilly SM, Camplejohn RS, Barnes DM, Millis RR, Allen D, Rubens RD, Richards MA: DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer 61: 671– 674, 1990. 34 O'Reilly SM, Camplejohn RS, Millis RR, Rubens RD, Richards MA: Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Eur J Cancer 26 (10): 1035– 1038, 1990. 35 Shankey TV, Rabinovitch PS, Bagwell B, Bauer KD, Duque RE, Hedley DW, Mayall BH, Wheeless LL: Guidelines for the implementation of clinical DNA flow cytometry. Cytometry 1993 (in press). 36 Sharma S, Mishra MC, Kapur BM, Verma K, Nath I: The prognostic significance of ploidy analysis in operable breast cancer. Cancer 68: 2612– 2616, 1991. 37 Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Ferno M, Killander D, Olsson H: Indicators of prognosis in node-negative breast cancer [see comments]. N Engl J Med 322: 1045– 1053, 1990. 38 Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Ferno M, Killander D, Olsson H, Ranstam J: Flow cytometry in primary breast cancer: Improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels. Br J Cancer 62: 786– 790, 1990. 39 Toikkanen S, Joensuu H, Klemi P: Nuclear DNA content as a prognostic factor in T1-2N0 breast cancer. Am J Clin Pathol 93: 471– 479, 1990. 40 Toikkanen S, Joensuu H, Klemi P: The prognostic significance of nuclear DNA content in invasive breast cancer—a study with long-term follow-up. Br J Cancer 60: 693– 700, 1989. 41 van der Linden JC, Lindeman J, Baak JP, Meijer CJ, Herman CJ: The Multivariate Prognostic Index and nuclear DNA content are independent prognostic factors in primary breast cancer patients. Cytometry 10: 56– 61, 1989. 42 Winchester DJ, Duda RB, August CZ, Goldschmidt RA, Wruck DM, Rademaker AW, Winchester DP, Merkel DE: The importance of DNA flow cytometry in node-negative breast cancer. Arch Surg 125: 886– 889, 1990. 43 Witzig TE, Gonchoroff NJ, Therneau T, Gilbertson DT, Wold LE, Grant C, Grande J, Katzmann JA, Ahmann DL, Ingle JN: DNA content flow cytometry as a prognostic factor for node-positive breast cancer: The role of multiparameter ploidy analysis and specimen sonication. Cancer 68: 1781– 1788, 1991. Citing Literature Volume14, Issue51993Pages 482-485 ReferencesRelatedInformation